Reported Earlier, AstraZeneca's TRUQAP Wins FDA Oncologic Drugs Advisory Committee Backing For PTEN-Deficient mHSPC; CAPItello-281 Shows 19% Risk Reduction In Disease Progression

ODAC overwhelming majority voted that TRUQAP plus abiraterone and ADT demonstrated a favorable benefit risk profile for patients based on the CAPItello-281 Phase III trial results

First and only targeted treatment combination to demonstrate benefit in this subtype of prostate cancer addresses significant unmet patient need